AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01441297
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 200mg bid, PO, daily until PD
Trial: NCT00202462
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 7.5 gm qd
Trial: NCT01568762
Drug: VAK694
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04434274
Drug: Micronized Purified Flavonoid Fraction
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
Trial: NCT01568762
Drug: VAK694 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT01568762
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT01568762
Drug: QAX576 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00042874
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00042874
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04110847
Drug: JING CEIH SHERN YUAN EXTRACT PILL
RxNorm normalized name: Timothy grass pollen extract Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use, 3#BID
Trial: NCT00835575
Drug: REMERON SolTab® 15 mg Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 15 mg, single-dose fasting
Trial: NCT02792842
Drug: ART-123 (3-day ART)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
Trial: NCT02792842
Drug: ART-123 (1-day ART)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
Trial: NCT05409339
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
Trial: NCT05409339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
Trial: NCT05095545
Drug: AV5080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsules with a white body
Trial: NCT00160459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral Daily for 12 weeks
Trial: NCT01837810
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800mg every 8 hours as needed for pain
Trial: NCT03338998
Drug: BAF312 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous (IV) infusion - 4.5mg/4.5mL
Trial: NCT03338998
Drug: Matching Placebo for BAF312 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo
Trial: NCT03338998
Drug: BAF312 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg film-coated tablet
Trial: NCT03338998
Drug: Matching Placebo for BAF312 tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg film-coated tablet matching placebo
Trial: NCT00745836
Drug: statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00447941
Drug: SCA-136
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00514865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg QD(once a day) for 8 weeks
Trial: NCT00003460
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT00620893
Drug: PEG- 400 based artificial tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
Trial: NCT02450578
Drug: DSM265 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSM265 400mg, single oral administration in a fed state
Trial: NCT02450578
Drug: Placebo to DSM265 400 mg
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to DSM265 400mg, single oral administration in a fed state
Trial: NCT00538239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 10 mg tablets taken by mouth for 5 days per week continuously
Trial: NCT01695239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04067947
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet
Trial: NCT02064387
Drug: GSK2857916
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
Trial: NCT01532635
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
Trial: NCT01269463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule without active drug
Trial: NCT01232829
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01843179
Drug: Sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally twice per day at home for 12 months
Trial: NCT02194244
Drug: RG1662 granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral administration of RG1662 immediate release granules
Trial: NCT02194244
Drug: RG1662 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral administration of film-coated RG1662 immediate release tablet
Trial: NCT01408446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule 48mg three times a day after meals 8 weeks
Trial: NCT01220050
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for hyperparathyroidism for 26 weeks
Trial: NCT03428724
Drug: Standard Preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
Trial: NCT01014741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after PV isolation prior to CFE ablation.
Trial: NCT03711500
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
Trial: NCT03711500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
Trial: NCT00002953
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01042665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT03113708
Drug: Heparin Sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
Trial: NCT02171585
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01954615
Drug: 20 mg ACT-281959 prodrug formulation I (Group B)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01081795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
Trial: NCT02486055
Drug: BPM31510 Oral Nanosuspension 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
Trial: NCT00920660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
Trial: NCT00920660
Drug: 0.25g SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
Trial: NCT00920660
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the last treatment period, subjects will receive 30 mg open-label prednisolone.
Trial: NCT00920660
Drug: 1g SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
Trial: NCT02748707
Drug: Arm1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
Trial: NCT02748707
Drug: Arm 2
RxNorm normalized name: Surgitube Arm 2 5/8x50"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
Trial: NCT01146106
Drug: Pravastatin Sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin Sodium Tablets 80 mg
Trial: NCT00456014
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
Trial: NCT02833103
Drug: Danshu Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshu Capsules (0.9g potid/day) for three months by oral
Trial: NCT03217838
Drug: AZD2811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
Trial: NCT01533376
Drug: Preservative free artificial tear gel.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative free artificial tear gel applied topically twice a day.
Trial: NCT01954615
Drug: Placebo (Groups A to F)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04824586
Drug: Fast-acting human insulin
RxNorm normalized name: Insulins and analogues for injection, fast-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.
Trial: NCT00516737
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo; one dose, treatment of a single migraine attack
Trial: NCT00968851
Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms: 1
Trial: NCT00968851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm: 3
Trial: NCT00968851
Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms: 2
Trial: NCT01547325
Drug: NanoDOX 1% doxycycline monohydrate Hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% doxycycline monohydrate hydrogel
Trial: NCT01547325
Drug: placebo hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo hydrogel
Trial: NCT00603759
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg qid
Trial: NCT00603759
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cap qid
Trial: NCT02926950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet. Route of administration: oral.
Trial: NCT00002764
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00366522
Drug: LXR-623
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02561091
Drug: AM-111 0.4 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02561091
Drug: AM-111 0.8 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03682601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquaphor/vehicle
Trial: NCT01995071
Drug: ABT-493
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01995071
Drug: ABT-530
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01995071
Drug: ABT-450/r/ABT-267, ABT-333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Trial: NCT01157078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, twice daily for 8 weeks
Trial: NCT01020474
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsules twice daily.
Trial: NCT01490567
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 5mg/d
Trial: NCT04257461
Drug: Fluoropyrimidine
RxNorm normalized name: Fluoropyrimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
Trial: NCT02485145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo, which consists of the VersaPro cream, will be utilized in the study.
Trial: NCT01891487
Drug: Track B
RxNorm normalized name: GNP TRUEtrack Blood Glucose System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refresh Tears applied to eyebrows
Trial: NCT00835146
Drug: COPEGUS™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 200 mg, single-dose fasting
Trial: NCT00236535
Drug: tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00812214
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet every night at bedtime
Trial: NCT01480297
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate 3 grams daily (1 gram TID with meals)
Trial: NCT01008280
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill tid
Trial: NCT04404361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching pacritinib 100 mg capsules
Trial: NCT02944448
Drug: CR845 tablet 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Trial: NCT02944448
Drug: CR845 tablet 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Trial: NCT02944448
Drug: CR845 tablet 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Trial: NCT02944448
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Trial: NCT01334034
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
Trial: NCT04859361
Drug: Aldara 5% Topical Cream
RxNorm normalized name: Aldara 5% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
Trial: NCT03616405
Drug: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
Trial: NCT03419403
Drug: Vasoconstrictor eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, eye drop
Trial: NCT04644809
Drug: LY3561774
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04644809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT00835692
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg Tablet
Trial: NCT00835692
Drug: Biaxin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Tablet
Trial: NCT02868242
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT03193398
Drug: Placebo oral capsule(s)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered once daily to patients with MDD for 8 weeks
Trial: NCT00646542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01695473
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
Trial: NCT00557219
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
Trial: NCT00245115
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03730272
Drug: analgesic drugs and methods
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patient will receive analgesic treatment at the discretion of the physician in charge
Trial: NCT00556660
Drug: [123I] AV-151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
Trial: NCT02211924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no